Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.
Sen, Triparna, Della Corte, Carminia M., Milutinovic, Snezana, Cardnell, Robert J., Diao, Lixia, Ramkumar, Kavya, Gay, Carl M., Stewart, C Allison, Fan, Youhong, Shen, Li, Hansen, Ryan J., Strouse, BrJournal:
Journal of Thoracic Oncology
DOI:
10.1016/j.jtho.2019.08.009
Date:
August, 2019
Fichier:
PDF, 3.62 MB
2019
File converter
Plus de résultats de recherche
More benefits 
